Important Project of Common European Interest: IPCEI Med4Cure health

Strategic project at european level, with the participation of several countries, which will improve research and development of industrial capacities in Europe.

Summary sheet of the assistance

Action

Financing to spanish companies participating in the IPCEI Med4Cure.

Beneficiaries

Companies set out in decision C (2024) final language.

a) Sylentis, SAU, as a direct participant in the IPCEI Med4Cure.

(b) Laboratorio Reig Jofre, SA Rovi; Pharmaceutical Laboratories, inc.; Medichem, inc.; Minoryx Therapeutics, SL, and Oryzon Genomics, SA, as associate participants in the IPCEI Med4Cure, according to annex I to the decision.

Call type

Convening of direct allocation to r & D projects and industrial first deployment for the direct partner and r & D projects for partnership participants.

Submission deadline

The call will be open from 17 december 2024 to 23 january 2025, until 12:00 o'clock, peninsular time.

Call Status

Open.

Type of assistance

Grants are awarded on a direct.

Call budget

110.000.000 euros.

Characteristics of the assitance

Subsidies.

The participant has a direct aid intensity of 100% up to €21.1 million.

The intensity of participants will be partners for an r & D in accordance with the RGEC.

Characteristics of the project

The duration of projects will be until 31 august 2026, without possibility of further extensions.

Call funding

Financing of funds of the mechanism for the recovery and Resilience.

May include third-party funds

It is incompatible with other funds.

Allows for generating motivated reports

Yes, once granted aid.

Specific objectives

The activities in question of the direct partner will be included in the documentation provided in the notification of aid to the european commission (Project portfolio and Funding gap) and authorized in decision C (2024) final language.

In the case of partnership participants include feasibility studies and r & D activities in accordance with the proposal.

Gastos elegibles

See call.

Incentive effect

The date of commencement of activities should be after january 2023.

Accumulation and incompatibilities of additional aid perception

In the case of direct participant in the IPCEI, the aid granted may be joined with other aid as long as the sum total of public funding granted in connection with the same qualified costs must not exceed the quantity authorized in decision C (2024) final language.

In the case of participants IPCEI partners, the aid provided under this order will be incompatible with any other emergency assistance, upon or after granted, whose purpose is the same purpose.

In any case, the entities beneficiaries are obliged to report on the implementation of other aid, subsidies, income or resources to fund the activities subsidised, once they are aware of.

Regulatory framework

Decisión C (2024) final language, of 24 may 2024, of the european commission for the direct partner.

Regulation (EU) no. 651/2014, in partnership participants.

Regulation (EU) 2021/241 of the european parliament and of the council of 12 february 2021.

Law 38/2003 of 17 november, General grants, and its regulations issued by royal decree 887/2006 of 21 july.

Few standards resulting from implementation.